Atrium Therapeutics
Atrium is seeking a Postdoctoral Scientist to develop and apply in vitro cardiac assays for siRNA-based antibody-oligonucleotide conjugate programs in rare genetic cardiomyopathies. The role involves using human iPSC-derived cardiomyocytes and engineered cardiac tissues to assess calcium handling and contractile function while connecting functional findings with target knockdown to characterize pharmacology. This hands-on laboratory position offers ownership of a defined research project with opportunities to publish and present work externally.
Our vision is to pioneer precision RNA medicines for the heart and profoundly improve the lives of people impacted by cardiac diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Atrium Therapeutics.
27% above the average for this role
Senior Scientist, siRNA Pipeline Development, Ex-hepatic
AbbVie
Senior Scientist (Oligonucleotide Conjugation)
Amgen
Oligo Discovery Chemistry Principal Scientist
GSK plc
Scientist, Oligonucleotide Synthesis
GSK plc
Director of In Vitro Pharmacology
Eli Lilly and Company
Accelerating impact through partnerships
Inceptive